Secondary hyperparathyroidism refers to the excessive secretion of parathyroid hormone by the parathyroid glands in response to hypocalcemia and associated hyperplasia of the glands.
In the treatment of secondary hyperparathyroidism due to chronic kidney disease on dialysis calcimimetics do not appear to affect the risk of early death. It does decrease the need for a parathyroidectomy but caused more issues with low blood calcium levels and vomiting.
Market Analysis and Insights: Global Secondary Hyperparathyroidism Treatment Market
The global Secondary Hyperparathyroidism Treatment market size is projected to reach US$ 3317.1 million by 2026, from US$ 3143.6 million in 2020, at a CAGR of 5.1%% during 2021-2026.
Global Secondary Hyperparathyroidism Treatment Scope and Market Size
Secondary Hyperparathyroidism Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Secondary Hyperparathyroidism Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
Amgen
OPKO Health
AbbVie
Astellas Pharma
Roche
KAI Pharmaceuticals
Kyowa Hakko Kirin
Leo Pharma
Takeda
Sanofi
Deltanoid Pharmaceuticals
Secondary Hyperparathyroidism Treatment Breakdown Data by Type
Surgery
Drugs
Vitamin D
Calcimimetics
Phosphate Binders
Secondary Hyperparathyroidism Treatment Breakdown Data by Application
Hospital Pharmacies
Retail Pharmacies
In the treatment of secondary hyperparathyroidism due to chronic kidney disease on dialysis calcimimetics do not appear to affect the risk of early death. It does decrease the need for a parathyroidectomy but caused more issues with low blood calcium levels and vomiting.
Market Analysis and Insights: Global Secondary Hyperparathyroidism Treatment Market
The global Secondary Hyperparathyroidism Treatment market size is projected to reach US$ 3317.1 million by 2026, from US$ 3143.6 million in 2020, at a CAGR of 5.1%% during 2021-2026.
Global Secondary Hyperparathyroidism Treatment Scope and Market Size
Secondary Hyperparathyroidism Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Secondary Hyperparathyroidism Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
Amgen
OPKO Health
AbbVie
Astellas Pharma
Roche
KAI Pharmaceuticals
Kyowa Hakko Kirin
Leo Pharma
Takeda
Sanofi
Deltanoid Pharmaceuticals
Secondary Hyperparathyroidism Treatment Breakdown Data by Type
Surgery
Drugs
Vitamin D
Calcimimetics
Phosphate Binders
Secondary Hyperparathyroidism Treatment Breakdown Data by Application
Hospital Pharmacies
Retail Pharmacies
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Secondary Hyperparathyroidism Treatment Revenue
1.4 Market by Type
1.4.1 Global Secondary Hyperparathyroidism Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Surgery
1.4.3 Drugs
1.4.4 Vitamin D
1.4.5 Calcimimetics
1.4.6 Phosphate Binders
1.5 Market by Application
1.5.1 Global Secondary Hyperparathyroidism Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Secondary Hyperparathyroidism Treatment Market Perspective (2015-2026)
2.2 Global Secondary Hyperparathyroidism Treatment Growth Trends by Regions
2.2.1 Secondary Hyperparathyroidism Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Secondary Hyperparathyroidism Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Secondary Hyperparathyroidism Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Secondary Hyperparathyroidism Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Secondary Hyperparathyroidism Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Secondary Hyperparathyroidism Treatment Players by Market Size
3.1.1 Global Top Secondary Hyperparathyroidism Treatment Players by Revenue (2015-2020)
3.1.2 Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Secondary Hyperparathyroidism Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Secondary Hyperparathyroidism Treatment Market Concentration Ratio
3.2.1 Global Secondary Hyperparathyroidism Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Secondary Hyperparathyroidism Treatment Revenue in 2019
3.3 Secondary Hyperparathyroidism Treatment Key Players Head office and Area Served
3.4 Key Players Secondary Hyperparathyroidism Treatment Product Solution and Service
3.5 Date of Enter into Secondary Hyperparathyroidism Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Secondary Hyperparathyroidism Treatment Historic Market Size by Type (2015-2020)
4.2 Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
5.2 Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
6.2 Secondary Hyperparathyroidism Treatment Key Players in North America (2019-2020)
6.3 North America Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
6.4 North America Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
7.2 Secondary Hyperparathyroidism Treatment Key Players in Europe (2019-2020)
7.3 Europe Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
7.4 Europe Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
8 China
8.1 China Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
8.2 Secondary Hyperparathyroidism Treatment Key Players in China (2019-2020)
8.3 China Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
8.4 China Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
9.2 Secondary Hyperparathyroidism Treatment Key Players in Japan (2019-2020)
9.3 Japan Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
9.4 Japan Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
10.2 Secondary Hyperparathyroidism Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
11 India
11.1 India Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
11.2 Secondary Hyperparathyroidism Treatment Key Players in India (2019-2020)
11.3 India Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
11.4 India Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
12.2 Secondary Hyperparathyroidism Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
12.4 Central & South America Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Amgen
13.1.1 Amgen Company Details
13.1.2 Amgen Business Overview
13.1.3 Amgen Secondary Hyperparathyroidism Treatment Introduction
13.1.4 Amgen Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020))
13.1.5 Amgen Recent Development
13.2 OPKO Health
13.2.1 OPKO Health Company Details
13.2.2 OPKO Health Business Overview
13.2.3 OPKO Health Secondary Hyperparathyroidism Treatment Introduction
13.2.4 OPKO Health Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.2.5 OPKO Health Recent Development
13.3 AbbVie
13.3.1 AbbVie Company Details
13.3.2 AbbVie Business Overview
13.3.3 AbbVie Secondary Hyperparathyroidism Treatment Introduction
13.3.4 AbbVie Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.3.5 AbbVie Recent Development
13.4 Astellas Pharma
13.4.1 Astellas Pharma Company Details
13.4.2 Astellas Pharma Business Overview
13.4.3 Astellas Pharma Secondary Hyperparathyroidism Treatment Introduction
13.4.4 Astellas Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.4.5 Astellas Pharma Recent Development
13.5 Roche
13.5.1 Roche Company Details
13.5.2 Roche Business Overview
13.5.3 Roche Secondary Hyperparathyroidism Treatment Introduction
13.5.4 Roche Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.5.5 Roche Recent Development
13.6 KAI Pharmaceuticals
13.6.1 KAI Pharmaceuticals Company Details
13.6.2 KAI Pharmaceuticals Business Overview
13.6.3 KAI Pharmaceuticals Secondary Hyperparathyroidism Treatment Introduction
13.6.4 KAI Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.6.5 KAI Pharmaceuticals Recent Development
13.7 Kyowa Hakko Kirin
13.7.1 Kyowa Hakko Kirin Company Details
13.7.2 Kyowa Hakko Kirin Business Overview
13.7.3 Kyowa Hakko Kirin Secondary Hyperparathyroidism Treatment Introduction
13.7.4 Kyowa Hakko Kirin Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.7.5 Kyowa Hakko Kirin Recent Development
13.8 Leo Pharma
13.8.1 Leo Pharma Company Details
13.8.2 Leo Pharma Business Overview
13.8.3 Leo Pharma Secondary Hyperparathyroidism Treatment Introduction
13.8.4 Leo Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.8.5 Leo Pharma Recent Development
13.9 Takeda
13.9.1 Takeda Company Details
13.9.2 Takeda Business Overview
13.9.3 Takeda Secondary Hyperparathyroidism Treatment Introduction
13.9.4 Takeda Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.9.5 Takeda Recent Development
13.10 Sanofi
13.10.1 Sanofi Company Details
13.10.2 Sanofi Business Overview
13.10.3 Sanofi Secondary Hyperparathyroidism Treatment Introduction
13.10.4 Sanofi Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.10.5 Sanofi Recent Development
13.11 Deltanoid Pharmaceuticals
10.11.1 Deltanoid Pharmaceuticals Company Details
10.11.2 Deltanoid Pharmaceuticals Business Overview
10.11.3 Deltanoid Pharmaceuticals Secondary Hyperparathyroidism Treatment Introduction
10.11.4 Deltanoid Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
10.11.5 Deltanoid Pharmaceuticals Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Secondary Hyperparathyroidism Treatment Revenue
1.4 Market by Type
1.4.1 Global Secondary Hyperparathyroidism Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Surgery
1.4.3 Drugs
1.4.4 Vitamin D
1.4.5 Calcimimetics
1.4.6 Phosphate Binders
1.5 Market by Application
1.5.1 Global Secondary Hyperparathyroidism Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Secondary Hyperparathyroidism Treatment Market Perspective (2015-2026)
2.2 Global Secondary Hyperparathyroidism Treatment Growth Trends by Regions
2.2.1 Secondary Hyperparathyroidism Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Secondary Hyperparathyroidism Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Secondary Hyperparathyroidism Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Secondary Hyperparathyroidism Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Secondary Hyperparathyroidism Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Secondary Hyperparathyroidism Treatment Players by Market Size
3.1.1 Global Top Secondary Hyperparathyroidism Treatment Players by Revenue (2015-2020)
3.1.2 Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Secondary Hyperparathyroidism Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Secondary Hyperparathyroidism Treatment Market Concentration Ratio
3.2.1 Global Secondary Hyperparathyroidism Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Secondary Hyperparathyroidism Treatment Revenue in 2019
3.3 Secondary Hyperparathyroidism Treatment Key Players Head office and Area Served
3.4 Key Players Secondary Hyperparathyroidism Treatment Product Solution and Service
3.5 Date of Enter into Secondary Hyperparathyroidism Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Secondary Hyperparathyroidism Treatment Historic Market Size by Type (2015-2020)
4.2 Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
5.2 Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
6.2 Secondary Hyperparathyroidism Treatment Key Players in North America (2019-2020)
6.3 North America Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
6.4 North America Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
7.2 Secondary Hyperparathyroidism Treatment Key Players in Europe (2019-2020)
7.3 Europe Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
7.4 Europe Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
8 China
8.1 China Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
8.2 Secondary Hyperparathyroidism Treatment Key Players in China (2019-2020)
8.3 China Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
8.4 China Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
9.2 Secondary Hyperparathyroidism Treatment Key Players in Japan (2019-2020)
9.3 Japan Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
9.4 Japan Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
10.2 Secondary Hyperparathyroidism Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
11 India
11.1 India Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
11.2 Secondary Hyperparathyroidism Treatment Key Players in India (2019-2020)
11.3 India Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
11.4 India Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Secondary Hyperparathyroidism Treatment Market Size (2015-2020)
12.2 Secondary Hyperparathyroidism Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Secondary Hyperparathyroidism Treatment Market Size by Type (2015-2020)
12.4 Central & South America Secondary Hyperparathyroidism Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Amgen
13.1.1 Amgen Company Details
13.1.2 Amgen Business Overview
13.1.3 Amgen Secondary Hyperparathyroidism Treatment Introduction
13.1.4 Amgen Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020))
13.1.5 Amgen Recent Development
13.2 OPKO Health
13.2.1 OPKO Health Company Details
13.2.2 OPKO Health Business Overview
13.2.3 OPKO Health Secondary Hyperparathyroidism Treatment Introduction
13.2.4 OPKO Health Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.2.5 OPKO Health Recent Development
13.3 AbbVie
13.3.1 AbbVie Company Details
13.3.2 AbbVie Business Overview
13.3.3 AbbVie Secondary Hyperparathyroidism Treatment Introduction
13.3.4 AbbVie Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.3.5 AbbVie Recent Development
13.4 Astellas Pharma
13.4.1 Astellas Pharma Company Details
13.4.2 Astellas Pharma Business Overview
13.4.3 Astellas Pharma Secondary Hyperparathyroidism Treatment Introduction
13.4.4 Astellas Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.4.5 Astellas Pharma Recent Development
13.5 Roche
13.5.1 Roche Company Details
13.5.2 Roche Business Overview
13.5.3 Roche Secondary Hyperparathyroidism Treatment Introduction
13.5.4 Roche Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.5.5 Roche Recent Development
13.6 KAI Pharmaceuticals
13.6.1 KAI Pharmaceuticals Company Details
13.6.2 KAI Pharmaceuticals Business Overview
13.6.3 KAI Pharmaceuticals Secondary Hyperparathyroidism Treatment Introduction
13.6.4 KAI Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.6.5 KAI Pharmaceuticals Recent Development
13.7 Kyowa Hakko Kirin
13.7.1 Kyowa Hakko Kirin Company Details
13.7.2 Kyowa Hakko Kirin Business Overview
13.7.3 Kyowa Hakko Kirin Secondary Hyperparathyroidism Treatment Introduction
13.7.4 Kyowa Hakko Kirin Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.7.5 Kyowa Hakko Kirin Recent Development
13.8 Leo Pharma
13.8.1 Leo Pharma Company Details
13.8.2 Leo Pharma Business Overview
13.8.3 Leo Pharma Secondary Hyperparathyroidism Treatment Introduction
13.8.4 Leo Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.8.5 Leo Pharma Recent Development
13.9 Takeda
13.9.1 Takeda Company Details
13.9.2 Takeda Business Overview
13.9.3 Takeda Secondary Hyperparathyroidism Treatment Introduction
13.9.4 Takeda Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.9.5 Takeda Recent Development
13.10 Sanofi
13.10.1 Sanofi Company Details
13.10.2 Sanofi Business Overview
13.10.3 Sanofi Secondary Hyperparathyroidism Treatment Introduction
13.10.4 Sanofi Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
13.10.5 Sanofi Recent Development
13.11 Deltanoid Pharmaceuticals
10.11.1 Deltanoid Pharmaceuticals Company Details
10.11.2 Deltanoid Pharmaceuticals Business Overview
10.11.3 Deltanoid Pharmaceuticals Secondary Hyperparathyroidism Treatment Introduction
10.11.4 Deltanoid Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2015-2020)
10.11.5 Deltanoid Pharmaceuticals Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
